FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.
2 reports, 1 independent
Updated Sep 11
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.